A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

AlphaDBS System for Parkinsons Disease Receives CE Mark

AlphaDBS System is the first rechargeable deep brain neurostimulation system that can continuously record and interpret bioelectrical neuronal activity in the brain areas where stimulation is delivered reports Newronika, a spin-off of world-class neurological research center Policlinico of Milan and the University of Milan.

AlphaDBS’s proprietary sensing technology records noise-free local field potentials while electrical stimulation is delivered.

The AlphaDBS system is also capable of closed-loop stimulation in which the current delivered is automatically adjusted for the individual needs of each patient, a true revolution in DBS care and personalized medicine. This feature is currently under clinical evaluation. When available, it will be the most important innovation in the DBS field. The device also collects brain signals critical to developing new treatments using a first-of-its-kind telemonitoring platform between patients and physicians.

“The ability to collect real-time brainwave information from patients with Parkinson’s disease during electrical stimulation treatment provides clinicians with a unique opportunity to understand the disease process and how effective stimulation is while patients participate in normal activities of life,” said Lorenzo Rossi, co-founder and CEO of Newronika.

“DBS is an established treatment for treating Parkinson’s disease but there has been minimal innovation in how to deliver the therapy. The capability of AlphaDBS to collect real-time information from the brain with the potential to close the loop is a major advancement for a personalized therapy, which is only delivered when needed. Such an ‘on demand’ therapy holds the promise of better efficacy and less adverse effects than continuous stimulation,” according to Jens Volkmann, MD, Professor and Chairman Department of Neurology, University Hospital Würzburg, Germany.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy